Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorThe Cleveland Clinic
About this trial
The aim of the proposed study is to estimate the incidence of Mild Autonomous Cortisol Secretion (MACS) in patients with Adrenal Incidentaloma (AI) and evaluate the available diagnostic tests to determine the most sensitive and specific combination of tests for assessing MACS from adrenal adenoma for prediction of the phenotype associated with cortisol excess. As well as following the patients for 4 years and see if anything changes.
Eligibility criteria
Qualifiers
Patients ages 18 years and older.
Presence of adrenal incidentaloma by cat scan (CT) or magnetic resonance imaging (MRI) examination.
1-mg Dexamethasone suppression test cortisol ≤ 5 μg/dL with adequate dexamethasone level.
Disqualifiers
1-mg Dexamethasone suppression test cortisol > 5 μg/dL with adequate dexamethasone level. Patients who fail to suppress below this level will be considered to have Cushing's syndrome and will be referred for appropriate treatment.
Current or recent (3 months) history of use of glucocorticoid medication (including joint injections of steroids).
History of uncontrolled hypertension or history of hypertension with more than 2 medications.
History of uncontrolled type 2 Diabetes Mellitus or history of diabetes mellitus with A1c>7.5.
Trial design
Treatments tested in this trial
- Various labs and imaging tests
Treatment groups
No treatment groups listed
Sponsors and collaborators
The Cleveland Clinic
Lead sponsor
RECORDATI GROUP
Collaborator
Source ClinicalTrials.gov